Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
They actively reduce the side effects that make GLP-1 therapy miserable for many people
October 7, 2024
Patients with established cardiovascular disease (heart attack, stroke history) who benefit from semaglutides proven MACE reduction (SELECT trial) Adolescents aged 1217 with obesity Wegovy is the only approved GLP-1 option in this age group Patients who prefer or need an oral medication option (Rybelsus tablets for type 2 diabetes) Those for whom semaglutide is more affordable or better covered by insurance Patients with metabolic dysfunction-associated steatohepatitis (MASH) Wegovy HD received approval for this indication in 2025 First-time GLP-1 users who want to start with the medication with the longest real-world safety track record Frequently Asked Questions Is tirzepatide stronger than semaglutide
confirm your specific checkout total before completing a transaction
\Cardiovascular Benefits: Reductions in systolic BP, LDL cholesterol, and inflammatory markers
US$ 25.08
US$ 29.12
US$ 25.00
